GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (LTS:0A9G) » Definitions » EPS (Diluted)

Mereo BioPharma Group (LTS:0A9G) EPS (Diluted) : $-0.30 (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mereo BioPharma Group EPS (Diluted)?

Mereo BioPharma Group's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.30.

Mereo BioPharma Group's EPS (Basic) for the three months ended in Sep. 2024 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.30.

Mereo BioPharma Group's EPS without NRI for the three months ended in Sep. 2024 was $-0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.24.

During the past 3 years, the average EPS without NRIGrowth Rate was 39.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 42.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Mereo BioPharma Group's highest 3-Year average EPS without NRI Growth Rate was 45.30% per year. The lowest was 4.60% per year. And the median was 35.60% per year.


Mereo BioPharma Group EPS (Diluted) Historical Data

The historical data trend for Mereo BioPharma Group's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group EPS (Diluted) Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only -2.56 -3.27 -0.34 -0.35 -0.20

Mereo BioPharma Group Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.05 -0.05 -0.10 -0.10

Competitive Comparison of Mereo BioPharma Group's EPS (Diluted)

For the Biotechnology subindustry, Mereo BioPharma Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's PE Ratio falls into.



Mereo BioPharma Group EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Mereo BioPharma Group's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-29.466-0)/131.891
=-0.22

Mereo BioPharma Group's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-15.001-0)/154.029
=-0.10

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mereo BioPharma Group  (LTS:0A9G) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mereo BioPharma Group EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines